Halozyme Therapeutics - HALO Stock Forecast, Price & News

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Analysts Set New Price Targets

HALO has been the topic of several analyst reports. The Goldman Sachs Group lifted their target price on shares of Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 26th. StockNews.com downgraded shares of Halozyme Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 11th. Finally, SVB Leerink initiated coverage on shares of Halozyme Therapeutics in a research note on Monday, May 23rd. They issued an "outperform" rating and a $52.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $52.33.

Halozyme Therapeutics Trading Down 2.4 %

NASDAQ:HALO traded down $1.07 during trading hours on Wednesday, hitting $43.41. The company had a trading volume of 1,435,768 shares, compared to its average volume of 1,111,055. The company has a market capitalization of $5.98 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.67 and a beta of 1.20. The stock has a 50-day moving average price of $46.71 and a 200 day moving average price of $41.89. Halozyme Therapeutics has a 52 week low of $31.36 and a 52 week high of $52.98. The company has a debt-to-equity ratio of 3.91, a current ratio of 2.72 and a quick ratio of 2.23.

Halozyme Therapeutics (NASDAQ:HALO - Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.06. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The business had revenue of $152.37 million for the quarter, compared to analysts' expectations of $156.00 million. During the same quarter in the previous year, the business posted $0.63 earnings per share. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. On average, equities research analysts predict that Halozyme Therapeutics will post 2.06 EPS for the current fiscal year.